In this issue, Meyer and colleagues report a large and well-conducted cohort study that demonstrates that the effectiveness of the biosimilar CT-P13 is equivalent to that of infliximab in infliximab-naive patients with Crohn disease. The editorialists discuss the results and the assurance they provide about the effectiveness and safety of biosimilars.
from A via a.sfakia on Inoreader https://ift.tt/2GkaoRs
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,